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Abstract
Prion diseases are transmissible fatal neurodegenerative disorders affecting humans and animals. A central step in disease
progression is the accumulation of a misfolded form (PrPSc) of the host encoded prion protein (PrPC) in neuronal and non-
neuronal tissues. The involvement of peripheral tissues in preclinical states increases the risk of accidental transmission. On
the other hand, detection of PrPSc in non-neuronal easy-accessible compartments such as muscle may offer a novel
diagnostic tool. Primate models have proven invaluable to investigate prion diseases. We have studied the deposition of
PrPSc in muscle and central nervous system of rhesus monkeys challenged with sporadic Creutzfeldt-Jakob disease (sCJD),
variant CJD (vCJD) and bovine spongiform encephalopathy (BSE) in preclinical and clinical stage using biochemical and
morphological methods. Here, we show the preclinical presence of PrPSc in muscle and central nervous system of rhesus
monkeys experimentally infected with vCJD.
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Introduction
Prion diseases are transmissible neurodegenerative disorders
characterized by neuronal loss, astrocytosis and deposition of the
pathogenic isoform (PrPSc) of the cellular prion protein (PrPC).
Conversion of physiological PrPC into pathogenic PrPSc plays a
major role in disease pathophysiology and PrPSc is a principal
component of prion infectivity [1,2,3]. PrPSc differs from PrPC in
its increased ß-sheet content, which renders it relatively resistant to
proteolytic digestion [4,5].
Prion diseases affect humans and animals alike and both
human-to-human and animal-to-human transmission may occur
[6]. Human prion diseases include sporadic, genetic and acquired
forms [7,8]. Different prion-isolates show specific clinical and
biochemical traits which are referred to as prion strains [9].
Sporadic Creutzfeldt-Jakob disease (sCJD) has unknown aetiology
and may result from spontaneous conversion of PrPC to PrPSc
[10]. Genetic Creutzfeldt-Jakob disease (gCJD) co-segregates with
mutations in the gene encoding the prion protein and is inherited
autosomal dominantly [11], whereas acquired forms are caused by
exposure to infectious human prions during medical or neurosur-
gical procedures (iatrogenic Creutzfeldt-Jakob disease, iCJD) or a
non-human prion source such as bovine spongiform encephalop-
athy (BSE)-prions (variant Creutzfeldt-Jakob disease, vCJD) [12].
Interhuman transmission of vCJD through blood transfusions has
occurred in several instances [6,13]. In contrast, no such
transmissions have been reported with other human prion diseases
such as sCJD. This demonstrates that peripheral tissues of vCJD
infected individuals harbouring relatively low prion titer may lead
to prion transmission following host-adaption.
Non-human primate studies using macaques as model organism
have been valuable in elucidating pathophysiology of prion
diseases [14,15,16,17]. Primate studies routinely assess animals
in clinical disease states, thus distribution of PrPSc during
subclinical disease has not been investigated in primates [16].
Detailed knowledge on the distribution of PrPSc in model
organisms closely resembling the human situation is important
because it allows evidence based decisions aimed at limiting the
spread of vCJD through iatrogenic procedures [18,19,20].
Furthermore, knowledge on the temporal kinetics of PrPSc
accumulation in tissue compartments, which are easily accessible
such as muscle may help in devising novel approaches for
diagnostic tests, aimed at detecting prion diseases at subclinical
stage.
Muscle biopsy has been proposed as a novel tool for diagnosing
human prion diseases [21]. PrPSc is detectable in muscle of a wide
range of human prion diseases and data from rodent studies show
presence of muscular PrPSc in preclinical stages [22,23,24,25].
We therefore systematically investigated the deposition of PrPSc
in muscle and central nervous system in rhesus monkeys
challenged with sCJD, vCJD and BSE-prions in preclinical and
clinically diseased animals using ultrasensitive western blotting,
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13906
ELISA and PET-blot. Our results show subclinical deposition of
PrPSc in muscle of vCJD infected primates. These results should be
taken into consideration when devising strategies aimed at limiting
iatrogenic transmission of vCJD. The variability of detection of
PrPSc in muscle of clinical and subclinical primates suggests
inhomogeneous distribution and challenges the idea of employing
muscle biopsy as a routine diagnostic tool in prion diseases.
Results
Clinical prion disease following intraperitoneal
application of vCJD and BSE
To investigate if intraperitoneal prion inoculation leads to the
development of clinical prion disease, we infected rhesus monkeys
with vCJD, sCJD and BSE-prions or saline intraperitoneally.
Animals were monitored until signs of prion disease were present
and the experiment was terminated 335 weeks post inoculation
(wpi). Incubation times until clinical signs of prion disease were
172 wpi for the vCJD infected animal and 212 wpi for the BSE
infected primate, whereas the sCJD infected primate did not show
any signs of prion disease until the experiment was terminated
(table 1).
Exponential increase of PrPSc in brains of vCJD infected
primates
To investigate pattern and amounts of PrPSc deposition in
preclinical primates, we performed a time course study in rhesus
monkeys infected with vCJD, sCJD and BSE or saline intraper-
itoneally. For vCJD, animals were sacrificed at three preclinical
time points (132 wpi (n = 1), 144 wpi (n = 1), 158 wpi (n = 1)), and
one clinical time point (172 wpi (n = 1)). For sCJD one monkey
was taken at 243 wpi. The other sCJD challenged monkey was
sacrificed at 335 wpi and both failed to develop clinical prion
disease within the observation period. For BSE, one animal was
taken preclinically (107 wpi) and one animal clinically (212 wpi)
(table 1). In order to assess PrPSc deposition in the central nervous
system (CNS) we performed standard and ultrasensitive NaPTA-
enhanced Western blot analysis of cerebellum and frontal cortex.
PrPSc could be detected in all preclinical and clinical vCJD
infected macaques. In contrast, PrPSc could only be detected in the
clinical BSE diseased animal, whereas no PrPSc deposition was
detectable in a preclinical BSE monkey as well as in both
preclinical sCJD infected animals (figure 1A, B).
The setup of the study allowed us to assess temporal
development of PrPSc accumulation in the CNS of vCJD-infected
monkeys. PrPSc could be detected as early as 132 wpi in vCJD
inoculated primates and the amount of PrPSc increased until
clinical disease (figure 1A). Densitometric analysis of western blots
showed exponential increase of PrPSc until 158 wpi, whereas PrPSc
amounts only increased moderately from 158 to 172 wpi
(figure 1C). Strain properties of BSE and vCJD as reflected by
the glycoprofile and running behaviour of the unglycosylated core
fragment of PrPSc remained unchanged (figure 1A, B). vCJD and
BSE-inoculated primates showed comparable sizes of unglycosy-
lated PrPSc core fragments and compatible glycosylation profiles
indicating congruent PrPSc-types (figure 1A, B).
Western blot findings could be confirmed by PET-blot of
cerebellum showing abundant deposits of PrPSc in monkeys
challenged with vCJD and BSE-prions at terminal prion disease
and faint PrPSc deposits in a subclinical, vCJD challenged animal
(figure 2). No PrPSc could be detected in cerebellum in either of
the sCJD-infected monkeys as well as the preclinical BSE-
challenged primate.
Preclinical detection of PrPSc in muscle of vCJD
inoculated primates
To assess whether and to what extent PrPSc can be found in
muscle we determined PrPSc contents using NaPTA-enhanced
Western blot analysis and PrPSc specific ELISA (summarized in
table 1). At 132 wpi, the earliest time point assessed for vCJD, no
PrPSc could be detected in either western blot or ELISA of arm,
tongue and heart (figure 3, western blot data for heart not shown).
In contrast, at 144 wpi, PrPSc appeared in heart and tongue
muscle but not in arm muscle with ELISA and western blot
(figure 3, western blot data for heart not shown). At 158 wpi, PrPSc
was demonstrated in arm and tongue by ELISA and western blot
(figure 3A, B), whereas PrPSc was below detection limit by either
method in heart (figure 3A, B). In the clinical diseased animal from
the vCJD cohort, peripheral PrPSc deposits were abundant in
tongue tissue when measured by western blot and ELISA, yet
PrPSc in heart could only be detected by ELISA and PrPSc in arm
tissue only by western blot. In the BSE cohort, no PrPSc could be
Table 1. Primates included in the study.
Group wpi
Clinical
disease Muscular PrPSc CNS PrPSc
Tongue Arm Heart
ELISA WB ELISA WB ELISA WB ELISA WB PET
vCJD 132 no 2 2 2 2 2 2 + + +
144 no + + 2 2 + + + + +
158 no + + + + 2 2 + + +
172 yes + + 2 + + 2 + + +
sCJD 243 no 2 2 2 2 2 2 2 2 2
335 no n.d. 2 n.d. 2 n.d. 2 n.d. 2 2
BSE 107 no 2 2 2 2 2 2 2 2 2
212 yes + + 2 2 2 2 n.d. + +
Mock 106 no n.d. 2 n.d. 2 n.d. 2 n.d. 2 2
222 no 2 2 2 2 2 2 n.d. 2 2
doi:10.1371/journal.pone.0013906.t001
Prion in Primate Muscle
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Figure 1. Biochemical analysis of PrPSc in the CNS. A) Western Blot analysis for PrPSc (frontal cortex) of vCJD, BSE and sCJD infected animals.
PrPSc could be demonstrated in the brains of preclinical vCJD and prion-diseased vCJD and BSE inoculated animals. In the vCJD cohort, PrPSc is
detectable (using NaPTA) in subclinical state 40 weeks before onset of symptoms. sCJD inoculated macaques did not show PrPSc at any time point in
cerebellum (data not shown) and frontal cortex in conventional as well as NaPTA enhanced Western blot. (* indicates prion-diseased animals). B)
PrPSc-glycotype analysis demonstrates comparable glycotypes of vCJD and BSE when transmitted to primates. Densitometric measurement of
relative band intensities for di-, mono- and unglycosylated form of PrPSc is shown in % of total signal. C) Quantification of PrPSc-signal shows initial
exponential increase of PrPSc until 158 wpi when PrPSc levels off. Relative amounts of PrPSc are shown in arbitrary units as quantified in three
independent experiments.
doi:10.1371/journal.pone.0013906.g001
Prion in Primate Muscle
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found preclinically in arm, tongue or heart muscle using either
method. The clinically affected BSE challenged primate showed
unambiguous deposition of PrPSc in tongue tissue only (figure 3A,
B). No PrPSc was observable in arm or heart. Both sCJD infected
primates did not show any PrPSc in the investigated muscle tissue
when assessed by western blot or ELISA (figure 3A, B, table 1).
PrPSc deposits are associated to nerve fibers as well as to
myocytes in tongue tissue
To investigate the distribution of PrPSc in tongue tissue of vCJD
infected primates we used PET blotting. Of the four investigated
animals only one showed detectable PrPSc. Tongue tissue from this
clinically diseased animal (172 wpi) was shown to contain PrPSc by
western blotting and ELISA (figure 3A, B). PrPSc labelling
occurred in linear fashion in addition to dot like deposits. By
directly correlating PET blot data with information from
consecutive sections processed for histology we were able to
identify an association of PrPSc with nerve fibers (linear deposits,
figure 4B, C) and myocytes (dot like deposits, figure 4B, C).
Discussion
The occurrence of human-to-human transmission of vCJD
prions trough medical interventions has lead to concerns regarding
the further development of the vCJD epidemic [26,27]. Although
a wealth of studies have provided us with detailed information on
the temporal and spatial kinetics of prion diseases in rodents, there
is an ongoing controversy on the preclinical distribution of prion
infectivity and PrPSc in human prion diseases [28,29]. Further-
more, the detailed analysis of PrPSc distribution in preclinical
prion disease in an animal model closely resembling the human
situation is a prerequisite for the validation of novel diagnostic
tools such as muscle biopsy [16].
Non-human primate models have been used to determine
transmission efficiency of sCJD, iCJD, vCJD or BSE [14,15,16].
Infectious brain homogenates have been applied intracerebrally,
intravenously, orally or intratonsillary. The transmissibility of human
prion diseases to non-human primates could be proven in any case
[14,15]. With our study we show that the intraperitoneal route,
which is widely used in rodent models of prion diseases, is also
effective in transmitting prion diseases in primates. Incubation
time to clinical prion disease after intraperitoneal inoculation of
BSE was comparable with oral infection [16,30] with 48 months
versus 47, 51 and 63 months respectively. For vCJD, no data are
available for oral prion application. Incubation times were 25 to
37 month after intratonsillar and/or intracerebral inoculation
[30]. In our study, one animal developed clinical disease after 40
months. Three other animals were taken preclinically 30, 32 and
34 months after prion challenge and PrPSc deposition could be
readily shown in brain tissue of all four monkeys. PrPSc could not
be detected in any of the investigated tissues using various methods
in two primates intraperitoneally inoculated with sCJD, 56 and 77
month post inoculation. In contrast, Herzog [30] could show
efficient transmission of sCJD with clinical prion disease 56 month
post infection. Besides disparity in the administration of prions,
these differences may be attributed to variations in prion titers of
the inocula.
The shortening of incubation time in our experiment between
BSE and vCJD inoculated macaques could be due to vCJD-strain
adaptation or differences of titers of infectious prions present in
inocula. Since prion titers were not determined in samples used in
this study, we cannot rule out that these differences are due to
Figure 2. PET blots of cerebellum. PET blots show prominent deposition of PrPSc in granular and molecular cell layers in clinically diseased vCJD
and BSE inoculated animals whereas the subclinical vCJD inoculated primate only shows faint PrPSc in granular and molecular cell layers (scale bar in
lower left image 1 mm).
doi:10.1371/journal.pone.0013906.g002
Prion in Primate Muscle
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prion titer variations. Nonetheless, other studies attribute shorting
of incubation times between BSE and vCJD to strain adaptation
effects using either intravenous or intracerebral routes of
inoculation [14].
However, none of the former studies addressed the question of
preclinical PrPSc distribution and the temporal development of
PrPSc deposition. In our study we could show a drastic increase of
PrPSc in the CNS of vCJD inoculated macaques over time.
Figure 3. Preclinical detection of PrPSc in muscle of vCJD inoculated primates. A) Western Blot analysis of PrPSc from NaPTA precipitated
arm and tongue tissue of sCJD, vCJD and BSE infected primates and controls show PrPSc in arm and tongue of subclinical vCJD challenged monkeys
and in clinically affected vCJD and BSE inoculated animals. sCJD infected macaques did not show any detectable PrPSc in arm or tongue. B) Detection
of PrPSc in arm, tongue and heart tissue from sCJD, vCJD and BSE infected primates and controls by ELISA. The scatter graph shows values (mean of
two independent experiments) for arm (circle), tongue (triangle) and heart (diamond). The cut-off is indicated by grey shade and values below were
considered as negative. PrPSc could be detected in tongue, arm and heart of healthy and clinically diseased vCJD inoculated animals. In BSE infected
animals PrPSc could only be detected in tongue tissue and in sCJD infected animals no PrPSc could be detected.
doi:10.1371/journal.pone.0013906.g003
Figure 4. Morphological analysis of tongue reveals PrPSc deposition in nerve fibers and myocytes. A) Histological analysis of tongue
from the clinical, vCJD infected macaque shows muscle fibers intermingled with peripheral nerves (Haematoxilin and Eosin staining, scale bar 50 mm).
B, C) PET blot (consecutive section from A) showing labelling of PrPSc. Higher magnification (C) of the insert shown in (B) revealed PrPSc staining of
longitudinal nerve fibers (arrow) and adjacent myocytes (triangles).
doi:10.1371/journal.pone.0013906.g004
Prion in Primate Muscle
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Interestingly, PrPSc accumulation seems to saturate the end of the
incubation time. This fact is also known from rodent models of
prion infection [31], but had never been demonstrated in primates
before.
The peripheral distribution of PrPSc has been well characterized
in rodent models of prion diseases [32,33]. Deposition of PrPSc in
muscle tissue had been shown in terminally sick hamsters
experimentally infected with scrapie [25], mice infected with
mouse adapted BSE and vCJD [24] as well as in sheep with
naturally occurring scrapie [34,35]. Preclinical PrPSc deposition in
muscle tissue could be demonstrated in experimentally infected
hamsters [36]. No preclinical PrPSc could be detected in heart
muscle [36]. PrPSc had also been detected in muscle of patients
suffering from sCJD, vCJD and iCJD [20,23]. Moreover, the tissue
distribution of PrPSc had been studied intensively in clinically
diseased vCJD patients where PrPSc could be detected in limb, but
not in tongue muscle [37,38]
Here we show the deposition of PrPSc in muscle tissue of
subclinical vCJD challenged primates. In agreement with other
studies, PrPSc deposits within the musculoskeletal system showed
patterns that are consistent with nerve fibers, yet we could also
observe PrPSc in structures resembling myocytes [23]. The fact
that highly innervated tongue muscle harbours more PrPSc than
arm muscle points to prominent involvement of nerve fibers in the
tongue not only in prion neuroinvasion [39] but also in PrPSc
accumulation. Quantification of PrPSc in muscle using Western
blotting or ELISA is variable. This may be due to inhomogeneous
distribution of PrPSc in the muscular compartment as visualized by
in situ detection methods for PrPSc such as PET blotting.
In summary, we could show that (i) PrPSc builds up
exponentially in the CNS of vCJD infected primates, (ii) PrPSc is
detectable in both CNS and the muscular compartment
preclinically in vCJD challenged rhesus monkeys, (iii) PrPSc
distribution in muscle tissue of clinical and subclinically infected
primates is inhomogeneous.
These data should be taken into consideration when devising
appropriate measures against iatrogenic transmission of prion




All procedures involving animals were performed in accordance
with European and German legal and ethical regulations (which
are in line with the recommended practices of the use of non-
human primates in research) and approved by the responsible
boards and authorities. Captive-bred rhesus macaques (Macacca
mulatta) were checked for absence of common primate pathogens
and were inoculated intraperitoneally with 10 ml of a 10%
homogenate in PBS of either BSE (mixture of cerebral cortex
specimen from five clinically BSE affected cattle) sCJD (prion
protein gene codon 129 MM, PrPSc type 2 according to [40]) and
vCJD (prion protein gene codon 129 MM, PrPSc type 4 according
to [40]; kindly provided by John Collinge, London, both cerebral
cortex). Control animals received saline only. Animals were
sacrificed at defined time points post inoculation and a subgroup
of animals were allowed to progress to clinical prion disease (see
table 1). These animals were sacrificed 4 weeks after onset of first
clinical symptoms of prion disease (slowness, weight loss,
trembling). The study was terminated 335 weeks post inoculation.
Tissues were either fixed in 4% formalin and prepared for
histological examination or snap-frozen in liquid nitrogen and
stored at 280uC for biochemical analyses.
Western Blot analysis
For Western blot analysis, brain samples (Cerebellum, frontal
cortex) were homogenised (FastPrep FP120, Qbiogene, Cedex,
France) at 10% (weight/volume, w/v) in buffer (150 mM NaCl, 1
% NP-40, 0.5 % DOC, 0.1 % SDS, 50 mM Tris-HCl pH 8.0) and
0.1 mg wet brain was digested with proteinase K (PK) (20 mg/ml)
for 45 min at 37uC. Digestion was stopped by adding 106 sample
buffer and boiling for 10 min. Samples were loaded on a 12%
SDS-PAGE gel transferred to PVDF membranes, blocked for
1 hour at room temperature in protein-free blocking buffer
(Thermo Scientific, Rockford, USA) and incubated overnight at
4uC with monoclonal anti-PrP antibody 6H4 raised against bovine
recombinant PrP, recognizing amino acids 144–152 of human PrP
(1:1000 in blocking buffer, Prionics, Schlieren, Switzerland). After
incubation for 1 hour at room temperature with an HRP-
conjugated anti-mouse secondary antibody (1:5000 in blocking
buffer), signal was detected using ECL femto reagent (Thermo
Scientific, Rockford, USA) and visualized with a BioRad
ChemiDoc imaging station and glycotpyes were evaluated using
published protocols [41].
Sodium phosphotungstic acid (NaPTA) precipitation
NaPTA precipitation was done according to published protocols
[21,42]) with minor changes. Muscle tissue (100 mg) was
dissociated in 900 ml buffer (25 mM HEPES (pH 7.2), 0.3 M
sucrose and 53,6 mg Liberase Blendzyme 2 (Roche, Mannheim,
Germany)). Samples were incubated for 30 min at 37uC and
homogenised (FastPrep FP120, Qbiogene, Cedex, France). 500 ml
of 10% (w/v) tissue homogenates and 500 ml of 4% (w/v) sarkosyl-
PBS were vortexed and incubated for 10 min at 37uC with
constant agitation. Benzonase (Novagen, Merck, Nottingham, UK
(50 U/ml)) and 1 mM MgCl2 were added and incubated at 37uC
for 30 min with vigorous shaking. 81.3 ml of a pre-warmed (to
37uC) 4% (w/v) NaPTA/170 mM MgCl2 solution (pH 7.4) was
added, vortexed and incubated with vigorous agitation for 30 min
at 37uC. Samples were centrifuged at 25,000 g for 30 min; pellets
were resuspended in 22.5 ml of 0.1% sarkosyl-PBS, followed by
proteinase K digestion (Roche, Mannheim, Germany) with a final
concentration of 20 mg/ml for 1 hour at 37uC and processed for
western blotting.
ELISA
ELISA measurements were performed using a modified version
of the Bio-Rad test (PlateliaHBSE, TeSeEH) that is also used for the
post mortem diagnosis of BSE in cattle according to published
protocols [34]. This kit uses two different monoclonal antibodies
allowing a sensitive detection of denatured PrP. PrPSc was purified
and concentrated from 50 mg fresh wet tissue homogenate using
the TeSeEH purification kit following the manufacturer’s instruc-
tions. This procedure included a PK treatment (0.4 mg/mg of
tissue) and a centrifugation step to concentrate PrPSc. The
corresponding pellet was denatured at 100uC in the presence of
a mixture of a chaotropic agent and a detergent. After fivefold
dilution in an appropriate buffer, denatured PrPSc was successively
reacted with capture antibody (Sha-31) and tracer antibody (Pri-
308) that were specific for the detection of primate prion protein.
Paraffin-embedded tissue (PET)-Blot
PET blots were performed according to published protocol
[43]. Briefly, formalin-fixed and decontaminated tissue was
embedded in paraffin, sectioned (5 mm), collected on a prewetted
nitrocellulose membrane (Bio-Rad, Hercules, USA) and com-
pletely dried at 55uC. After deparaffinization and rehydration, the
Prion in Primate Muscle
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membrane was washed in Tween 20 (0.1%) and dried for PrP
detection.
Prewetted membranes were digested with proteinase K (250
mg/ml) for 8 hours at 55uC. After washing, proteins were
denatured with 4 mol/l guanidine isothiocyanate for 15 minutes,
washed again and immunodetection was performed after prein-
cubation in blocking solution. Monoclonal antibody 12F10
recognizing amino acid 142–160 of human PrP (kindly provided
by J. Grassi; [44], commercially available through SPIbio,
Montigny, France) was used as primary antibody for at least
1 hour. Samples were washed again, incubated with alkaline-
phosphatase-coupled rabbit anti-mouse antibody (Dako, Glostrup,
Denmark) and detected using NBT/BCIP. Blots were evaluated
with an Olympus dissecting microscope (Olympus, Hamburg,
Germany).
Morphological analyses
Brain (cerebellum) or muscle tissue (tongue) was fixed with 4%
buffered formalin, inactivated by 98% formic acid for one hour
and embedded in paraffin. Sections were cut (3 mm) deparaffinised
and stained with haematoxylin and eosin according to standard
protocols [21].
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